Selecta Biosciences to Participate at the 2022 H.C. Wainwright BioConnect Conference
WATERTOWN, Mass., Jan. 05, 2022 - Selecta Biosciences (NASDAQ: SELB) announced a corporate update at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
WATERTOWN, Mass., Jan. 05, 2022 - Selecta Biosciences (NASDAQ: SELB) announced a corporate update at the H.C. Wainwright BioConnect Conference, taking place virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7 a.m. ET via the conference portal. Selecta is focused on developing tolerogenic therapies through its ImmTOR™ platform, aimed at mitigating unwanted immune responses. The company has various enzyme and gene therapy programs in its pipeline, which could enhance biologic therapies and address autoimmune diseases.
Details
News Market Reaction – SELB
The recorded move for SELB in the trading session of this news was -4.13%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WATERTOWN, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Company’s Management will provide a corporate update at the H.C. Wainwright BioConnect Conference, to be held virtually January 10-13, 2022.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. ET on Monday, January 10, 2022.
The webcast can be accessed here and an archived webcast will also be accessible in the Investors & Media section of the company’s website at www.selectabio.com.
About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is a clinical stage biotechnology company leveraging its ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. Selecta has several proprietary and partnered programs in its pipeline focused on enzyme therapies, gene therapies, and autoimmune diseases. Selecta Biosciences is headquartered in the Greater Boston area. For more information, please visit www.selectabio.com.
For Investors:
Bruce Mackle
LifeSci Advisors, LLC
+1-929-469-3859
bmackle@lifesciadvisors.com
For Media:
Brittany Leigh, Ph.D.
LifeSci Communications, LLC
+1-646-751-4366
bleigh@lifescicomms.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.